Skip to main content

Table 2 Cardiac function tests and treatments in the HF subjects

From: Parallel evolution of circulating FABP4 and NT-proBNP in heart failure patients

Variables HF subjects (n=179)
Heart rate (bpm) 76.2±13.6
QRS complex (ms) 120 (98–160)
QTc interval (ms) 449.0 (414.0–478.5)
PR interval (ms) 172.9±29.2
Normal sinus ECG rhythm (%) 68
6MWT (m) 375 (250–450)
MLHFQ 38.6±24.1
LVEDD (mm) 63.5±11.6
LVESD (mm) 50.5±11.2
AI 46.1±9.8
Left ventricular ejection fraction (%) 32 (25–39)
NT-proBNP (pmol/L) 679.8 (405.5–1177.9)
ACE inhibitor (%) 65
β-blocker (%) 61
Diuretic (%) 78
Statin (%) 37
  1. Abbreviations: HF, heart failure; ECG, electrocardiogram; 6MWT, six-minute walk test; MLHFQ, Minnesota Living with Heart Failure Questionnaire; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; AI, aortic insufficiency; NT-proBNP, N-terminal fragment of pro-B-type natriuretic peptide; ACE, angiotensin-converting enzyme.
  2. The data are presented as the mean±SD or median (interquartile range), unless otherwise indicated.